|1.||Scheen, André J: 5 articles (04/2015 - 06/2012)|
|2.||Scheen, A J: 2 articles (08/2015 - 04/2012)|
|3.||Cahn, Avivit: 2 articles (08/2015 - 06/2013)|
|4.||Kuritzky, Louis: 2 articles (10/2014 - 08/2010)|
|5.||Kendall, David M: 2 articles (07/2009 - 06/2009)|
|6.||Cuddihy, Robert M: 2 articles (07/2009 - 06/2009)|
|7.||Bergenstal, Richard M: 2 articles (07/2009 - 06/2009)|
|8.||Špinar, Jindřich: 1 article (11/2015)|
|9.||Špinarová, Lenka: 1 article (11/2015)|
|10.||Tziomalos, Konstantinos: 1 article (11/2015)|
|1.||Type 2 Diabetes Mellitus (MODY)
11/01/2015 - "The third clinical mortality study with gliptins in patients with diabetes mellitus type 2 was finished in 2015. "
10/01/2015 - "Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus."
03/15/2015 - "Erroneous event count in a meta-analysis (dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus)."
01/01/2014 - "To perform a systematic review and meta-analysis regarding the efficacy and safety of dipeptidyl peptidase-4 (DDP-4) inhibitors ("gliptins") for the treatment of type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment. "
05/01/2011 - "Pharmacologic targeting of PPARβ/δ is a promising approach in the treatment of patients with type 2 diabetes mellitus, especially in combination with dipeptidyl peptidase IV inhibitors."
04/01/2015 - "Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) occupy a growing place in the armamentarium of drugs used for the management of hyperglycemia in type 2 diabetes, although some safety concerns have been raised in recent years. "
06/01/2012 - "Dipeptidylpeptidase-4 inhibitors (gliptins), which are increasingly used to target hyperglycemia, also offer promising preliminary results regarding a possible reduction in CVD events. "
12/01/2012 - "Gliptins have revolutionised the treatment of Type 2 Diabetes Mellitus, addressing the hyperglycemia through its effects on the alpha and beta cells of the pancreas. "
10/01/2011 - "Gliptins represent a novel class of agents that improve beta cell health and suppress glucagon, resulting in improved post-prandial and fasting hyperglycemia. "
07/01/2015 - "Incretin-based, antidiabetes therapies (i.e., glucagon-like peptide [GLP]-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) have proven efficacy for the treatment of hyperglycemia. "
|3.||Hypoglycemia (Reactive Hypoglycemia)
05/01/2010 - "Gliptins determine a significant improvement of HbA1c in comparison with a placebo (-0.7 [-0.8:-0.6]), with a low risk of hypoglycemia. "
10/01/2014 - "Gliptins appear as promising agents with lesser tendency to cause hypoglycemia, but their long term safety and efficacy is yet to be established. "
09/11/2011 - "Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. "
11/01/2009 - "Gliptins show significant improvements in glycaemic control and are well tolerated, particularly with regard to weight change and hypoglycemia. "
06/01/2013 - "The gliptins are an optional second-line therapy after metformin; they are generally well tolerated with low risk of hypoglycemia. "
09/01/2014 - "[Gliptins: a safe and effective treatment of diabetes mellitus]."
12/01/2014 - "Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus."
09/01/2008 - "Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus."
01/01/2006 - "Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus."
09/01/2014 - " words: diabetes mellitus - dipeptidylpeptidase IV - gliptins - oral antidiabetics. "
|5.||Body Weight (Weight, Body)
11/01/2011 - "The advantages of gliptins include little side effects, body weight neutrality and potential protective effects on pancreatic beta cells. "
01/01/2006 - "Current information suggests dipeptidyl peptidase IV inhibitors are body weight neutral and are well tolerated. "
11/01/2011 - "GLP-1 agonists on the top of that consistently decrease body weight and blood pressure and their effects on diabetes compensation and likelihood of protective effects on beta cells is somewhat higher than those of gliptins. "
12/01/2013 - "Although both pharmacological approaches target GLP-1, important differences exist concerning the mode of administration (subcutaneous injection versus oral ingestion), the efficacy (better with GLP-1 agonists), the effects on body weight and systolic blood pressure (diminution with agonists versus neutrality with gliptins), the tolerance profile (nausea and possibly vomiting with agonists) and the cost (higher with GLP-1 receptor agonists). "
05/01/2009 - "These agents regulate glucose metabolism through multiple mechanisms, their use is associated with low rates of hypoglycemia, and they either do not affect body weight (dipeptidyl peptidase 4 inhibitors), or promote weight loss (glucagon-like peptide-1 receptor agonists). "
|1.||Glucagon-Like Peptide 1 (GLP 1)
|5.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
|10.||Hypoglycemic Agents (Hypoglycemics)